Kala Jayaram

Executive Medical Director, Pharmacovigilance
BioMarin Pharmaceutical Inc., Novato, CA, USA
Novato, California, United States

Presentation(s):

• OC 20.1 - Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1

  Sunday, June 25, 2023
  14:45 – 15:00 ET